Study design
Phase I part examined the combination of 12 intravenous administrations of weekly paclitaxel 80 mg/mIn the phase II part, patients were randomly assigned (1:1), stratified by baseline PD-L1 and CD73 status, and by the site to one of the two arms. In arm A, patients received 12 intravenous administrations of weekly 80 mg/m